YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a biopharmaceutical company specializing in enzymatic therapies for tissue repair, has launched a Phase III clinical trial for its product EscharEx®, ...

A major challenge in self-powered wearable sensors for health care monitoring is distinguishing different signals when they ...

A major challenge in self-powered wearable sensors for health care monitoring is distinguishing different signals when they occur at the same time. Researchers addressed this issue by uncovering a new ...

The South Carolina Burn Center at the Medical University of South Carolina and The Zucker Institute for Innovation ...

MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...

You're invited to publicize your 2024–2025 new product introductions in LCGC International. For our 2025 review, you may submit any product launched between May 2024 and March 2025. We have four forms ...

Novo Health Care Service and Encore Surgical Supplies developed the HealPACK as an innovative surgical dressing solution that enhances the post-surgery healing process, delivered to the patient's door ...

MediWound , an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers.

These non-living materials will have capabilities including self-healing, adaptation, growth, and programmability.

Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF) has made significant progress in its collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care.

Oleogel-S10 is an effective and well-tolerated long-term treatment for epidermolysis bullosa, including patients with severe forms of the disease.

Understanding the realities of C-section recovery can empower mothers, as they navigate their emotional and physical healing ...